Charles Bobin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Charles Bobin has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Saint-Charles
Institut Curie 4 INSERM U1330, Childhood Oncology Research Unit (CONCERT) Paris, France
28 shared publications - Gudrun Schleiermacher
Institut Curie, Paris, France
28 shared publications - Yasmine Iddir
Institut Curie 4 INSERM U1330, Childhood Oncology Research Unit (CONCERT) Paris, France
28 shared publications - Gaelle Pierron
Genetics Department Curie Institute & PSL Research University, Paris, France
27 shared publications - Olivier Delattre
INSERM U830, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, SIREDO Oncology Center, Institut Curie Research Center, Paris, France
27 shared publications - Angel Montero Carcaboso
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, Spain
15 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure 1 shows an overview of ITCC-P4 PDX engraftment success rates and multi-omics data availability
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure 1 shows an overview of ITCC-P4 PDX engraftment success rates and multi-omics data availability
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S2 shows methylation- and transcriptome-based analyses of ITCC-P4 PDX models
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S2 shows methylation- and transcriptome-based analyses of ITCC-P4 PDX models
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S3 displays a comparison of driver mutation profiles between ITCC-P4 PDX models and matched patient tumors.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S3 displays a comparison of driver mutation profiles between ITCC-P4 PDX models and matched patient tumors.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S4 shows the genomic characterization of ITCC-P4 PDX models and matched patient tumors.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S4 shows the genomic characterization of ITCC-P4 PDX models and matched patient tumors.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S5 shows genomic fidelity between ITCC-P4 PDX models and matched patient tumors.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S5 shows genomic fidelity between ITCC-P4 PDX models and matched patient tumors.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S7 shows Clonal evolution analyses of sequential PDX models.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S7 shows Clonal evolution analyses of sequential PDX models.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S6 displays the methylation-based tSNE analysis of serial PDX models across pediatric cancer entities.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Figure S6 displays the methylation-based tSNE analysis of serial PDX models across pediatric cancer entities.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Table 1: Table resuming the clinical, xenograft and data details for the PDX models in the ITCC-P4 cohort.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Table 1: Table resuming the clinical, xenograft and data details for the PDX models in the ITCC-P4 cohort.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Table 2:List of ITCC-P4 and reference samples included in DNA methylation analyses; PDX-tumor distance Manhattan scores; Methylation-inferred purity scores.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
Supplementary Table 2:List of ITCC-P4 and reference samples included in DNA methylation analyses; PDX-tumor distance Manhattan scores; Methylation-inferred purity scores.